News
ImmPACT Bio and Kalthera Complete Merger
ImmPACT Bio USA, Inc., a company developing novel cell therapies for treating cancer, announced its merger with Kalthera, Inc., a biotechnology company. Kalthera was founded by Yvonne Chen, Ph.D., Antoni Ribas, M.D., Ph.D., Cristina Puig Saus, Ph.D., and Jim Johnston, Ph.D., and emerged from UCLA. Click here to read more.
Kite, a Gilead Company and Appia Bio Announce Collaboration
Gilead Sciences Inc. said its Kite unit signed a collaboration and license agreement with biotechnology startup Appia Bio Inc. to research and develop allogeneic cell therapies for cancer. The technology is based on the work of UCLA Researcher and Professor, Lili Yang PhD. Click here to read more.
UCLA TDG Innovation Magazine July 2021
Read about our recent successes in the UCLA TDG Innovation Magazine July 2021
UCLA Professor Spotlights for LABEST 2021
LABEST PROFESSOR SPOTLIGHTS
Professor Spotlight Webinar Series is one of a kind initiative by UCLA TDG for UCLA’s scientific community to share their research, vision and major programs how they are working towards addressing critical unmet needs whilst, fostering a culture of entrepreneurship and innovation amongst the faculty members and the Los Angeles bioscience ecosystem.
Stem Cell Therapy for Stroke & Dementia - Dr. S. Thomas Carmichael
A one-time injection of an experimental stem cell therapy can repair brain damage and improve memory function in mice with conditions that replicate human strokes and dementia, a new UCLA study finds.
UCLA forms collaboration with Yuyu Pharma to develop drug for stroke recovery
UCLA forms collaboration with Yuyu Pharma to develop drug for stroke recovery
UCLA has formed a research collaboration with South Korea-based Yuyu Pharma to develop drugs that could help people recover after a stroke.
Yuyu will develop drug candidates and UCLA researchers will conduct preclinical trials that could lead to further development of new compounds.
